natgillin/translations-raw huggingface dataset:
Zinforo is a powder that is made up into a solution for infusion (drip) into a vein.
Zinforo je prašak od kojeg se priprema otopina za intravensku infuziju (drip).
Zinforo is administered by intravenous infusion over 60 minutes for all infusion volumes (50 ml, 100 ml or 250 ml) (see section 6.6).
Zinforo se primjenjuje intravenskom infuzijom tijekom 60 minuta kod svih infuzijskih volumena (50 ml, 100 ml ili 250 ml) (vidjeti dio 6.6).
Zinforo is contraindicated in patients with a history of hypersensitivity to cephalosporins.
Zinforo je kontraindiciran u bolesnika preosjetljivih na cefalosporine.
Zinforo is given as an infusion into a vein lasting 60 minutes.
Zinforo se primjenjuje intravenskom infuzijom tijekom 60 minuta.
Zinforo is indicated for the treatment of the following infections in adults and children from the age of 2 months (see sections 4.4 and 5.1):
Zinforo je indiciran za liječenje sljedećih infekcija u odraslih i djece u dobi od navršena 2 mjeseca nadalje (vidjeti dijelove 4.4 i 5.1):
Zinforo is used to treat children from the age of 2 months and adults with:
Zinforo se koristi za liječenje djece u dobi od navršena 2 mjeseca nadalje te odraslih koji imaju:
Zinforo must also not be used in patients who are hypersensitive to other antibiotics belonging to the cephalosporin class and those who are severely allergic to other beta- lactam antibiotics.
Lijek Zinforo ne smiju upotrebljavati ni bolesnici koji su preosjetljivi na druge antibiotike iz klase cefalosporina i bolesnici koji su izrazito alergični na druge beta-laktam antibiotike.
Zinforo must not be used in people who are hypersensitive (allergic) to ceftaroline fosamil or any of the other ingredients.
Lijek Zinforo ne smiju upotrebljavati osobe koje su preosjetljive (alergične) na ceftarolinfosamil ili bilo koji drugi sastojak lijeka.
Zinforo powder should be reconstituted with 20 ml of sterile water for injections.
Zinforo prašak se mora rekonstituirati s 20 ml sterilne vode za injekcije.
Zinforo should be used with caution in patients with a history of any other type of hypersensitivity reaction to penicillins or carbapenems.
Zinforo je potrebno koristiti s oprezom u bolesnika koji su imali bilo koju drugu vrstu reakcije preosjetljivosti na peniciline ili karbapeneme.
Zinforo should not be used in children below the age of 2 months as not enough data exist in these populations.
Zinforo se ne smije primjenjivati u djece mlađe od 2 mjeseca jer nema dovoljno podataka za tu skupinu bolesnika.
Zinforo was as effective as the other antibiotics in treating both skin and soft tissue infections and pneumonia in adults:
Lijek Zinforo bio je jednako djelotvoran kao i drugi antibiotici u liječenju infekcija kože i mekog tkiva te pneumonije u odraslih osoba:
Zinforo works by killing certain bacteria, which can cause serious infections.
Zinforo djeluje tako što ubija određene bakterije koje mogu uzrokovati ozbiljne infekcije.
ZIPPED SEALABLE BAG
ZAPEČAĆENA VREĆICA SA ZIP ZATVARAČEM
Zoely has no or negligible effect on your ability to drive and use machines.
Zoely ne utječe ili zanemarivo utječe na Vašu sposobnost upravljanja vozilima i rada sa strojevima.
Zoely is a medicine available as 24 white ‘active’ tablets that contain the active substances nomegestrol acetate (2.5 mg) and estradiol (1.5 mg), and four yellow ‘inactive’ (placebo) tablets that do not contain any active substance.
Zoely je lijek koji je dostupan u pakiranju koje sadrži 24 bijele „aktivne” tablete koje sadrže djelatne tvari nomegestrolacetat (2,5 mg) i estradiol (1,5 mg) i četiri žute „neaktivne” (placebo) tablete koje ne sadrže djelatne tvari.
Zoely is indicated for the prevention of pregnancy.
Zoely je indiciran za sprječavanje trudnoće.
Zoely is not indicated during pregnancy.
Zoely nije indiciran za uporabu tijekom trudnoće.
Zoely may also interfere with the working of other medicines – such as the anti-epileptic lamotrigine.
Zoely također može ometati djelovanje drugih lijekova - poput antiepileptika lamotrigina.
Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la Neuve BELGIUM
Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIJA
Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIUM
Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIJA
Zoetis Belgium SA Rue Laid Burniat, 1 1348 Louvain-la-Neuve BELGIUM
Zoetis Belgium SA Rue Laid Burniat, 1 1348 Louvain-la-Neuve BELGIJA
Zoetis Belgium SA, Rue Laid Burniat 1, 1348 Louvain-la-Neuve, BELGIUM
Zoetis Belgium SA, Rue Laid Burniat, 1, 1348 Louvain-la-Neuve, BELGIJA
Zoetis Lietuva UAB Tel: +370 5 2683634
Zoetis Lietuva UAB Tel: +370 526 83634
Zoetis RomâniaSRL Tel : +40 21 207 17 70
Zoetis România SRL Tel : +40 21 207 17 70
zoledroni c acid
zoledronatn a kiselina
Zoledronic acid
Placebo Zoledronatna kiselina
zoledronic acid
zoledronatn a kiselina
Zoledronic acid
Zoledronatna
Zoledronic acid
zoledronatna kiselina
Zoledronic acid (%)
Zoledronatna kiselina (%)
Zoledronic acid (N = 1,065) event rate (%)
Zoledronatna kiselina (N=1065) stopa događaja (%)
Zoledronic acid (N=1,065) event rate (%)
Zoledronatna kiselina (n=1065) stopa događaja (%)
Zoledronic acid (N=3,875) event rate (%)
Zoledronatna kiselina (N=3875) stopa događaja (%)
Zoledronic acid 4 mg
Zoledronat na kiselina 4 mg
Zoledronic acid 4 mg (N=86)
4 mg zoledronatne kiseline (N=86)
Zoledronic Acid 4 mg (N=86)
Zoledronatna kiselina 4 mg (N=86)
Zoledronic acid 4 mg reduced the risk of SREs by 41 % in a multiple event analysis (risk ratio=0.59, p=0.019) compared with placebo.
Prema analizi višestrukih događaja, zoledronatna kiselina u dozi od 4 mg smanjila je rizik od koštanog događaja za 41% (omjer rizika =0,59, p=0,019) u usporedbi s placebom.
Zoledronic acid 4 mg reduced the risk of SREs by 41% in a multiple event analysis (risk ratio=0.59, p=0.019) compared with placebo.
Prema analizi višestrukih događaja, zoledronatna kiselina u dozi od 4 mg smanjila je rizik od koštanog događaja za 41% (omjer rizika=0,59, p=0,019) naspram placeba.
Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by > 5 months, and reduced the annual incidence of events per patient - skeletal morbidity rate.
Zoledronatna kiselina u dozi od 4 mg značajno je smanjila udio bolesnika s najmanje jednim koštanim događajem, produljila medijan vremena do prvog koštanog događaja za > 5 mjeseci i smanjila godišnju incidenciju događaja po bolesniku – stopu koštanog pobola.
Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by > 5 months, and reduced the annual incidence of events per patient - skeletal morbidity rate.
Zoledronatna kiselina u dozi od 4 mg značajno je smanjila udio bolesnika s najmanje jednim koštanim događajem, produljila medijan vremena do prvog koštanog događaja za više od 5 mjeseci i smanjila godišnju incidenciju događaja po bolesniku – stopu koštanog pobola.
Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by > 5 months, and reduced the annual incidence of events per patient – skeletal morbidity rate.
Zoledronatna kiselina u dozi od 4 mg značajno je smanjila udio bolesnika s najmanje jednim koštanim događajem, produljila medijan vremena do prvog koštanog događaja za više od 5 mjeseci i smanjila godišnju incidenciju događaja po bolesniku – stopu koštanog pobola.
Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by > 5 months, and reduced the annual incidence of events per patient-skeletal morbidity rate.
Zoledronatna kiselina u dozi od 4 mg značajno je smanjila udio bolesnika s najmanje jednim koštanim događajem, produljila medijan vremena do prvog koštanog događaja za više od 5 mjeseci i smanjila godišnju incidenciju događaja po bolesniku – stopu koštanog pobola.
Zoledronic acid 4 mg was also studied in a double-blind, randomised, placebo-controlled trial in 228 patients with documented bone metastases from breast cancer to evaluate the effect of 4 mg zoledronic acid on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcaemia and adjusted for prior fracture), divided by the total risk period.
Zoledronatna kiselina od 4 mg također se ispitivala u dvostruko slijepom, randomiziranom, placebom kontroliranom ispitivanju u 228 bolesnika s potvrđenim koštanim metastazama raka dojke da bi se procijenio učinak 4 mg zoledronatne kiseline na omjer stope koštanih događaja izračunatog kao ukupni broj koštanih događaja (bez hiperkalcijemije i prilagođen s obzirom na prethodne prijelome) podijeljen s ukupnim rizičnim razdobljem.
Zoledronic acid 4 mg was also studied in a double-blind, randomised, placebo-controlled trial in 228 patients with documented bone metastases from breast cancer to evaluate the effect of zoledronic acid 4 mg on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcaemia and adjusted for prior fracture), divided by the total risk period.
Zoledronatna kiselina od 4 mg također se ispitivala u dvostruko slijepom, randomiziranom, placebom kontroliranom ispitivanju u 228 bolesnika s potvrđenim koštanim metastazama karcinoma dojke da bi se procijenio učinak 4 mg zoledronatne kiseline na omjer stope koštanih događaja izračunatog kao ukupni broj koštanih događaja (bez hiperkalcemije i prilagođen s obzirom na prethodne prijelome) podijeljen s ukupnim rizičnim razdobljem.
Zoledronic acid 8 mg (N=90)
8 mg zoledronatne kiseline (N=90)
Zoledronic acid 8 mg (N=90)
Zoledronatna kiselina 8 mg (N = 90)
Zoledronic acid 8 mg (N=90)
Zoledronatna kiselina 8 mg (N=90)
Zoledronic Acid Accord
Zoledronatna kiselina Accord
Zoledronic Acid Accord 4 mg/5 ml concentrate for solution for infusion
Zoledronatna kiselina Accord 4 mg/5 ml koncentrat za otopinu za infuziju
Zoledronic Acid Accord 4 mg/5 ml concentrate for solution for infusion Zoledronic acid
Zoledronatna kiselina Accord 4 mg/5 ml koncentrat za otopinu za infuziju zoledronatna kiselina
Zoledronic Acid Accord can also be used to treat the hypercalcaemia caused by tumours.
Zoledronatna kiselina Accord može se koristiti za liječenje odraslih bolesnika s hiperkalcemijom izazvanom tumorom.
Zoledronic Acid Accord can only be obtained with a prescription and must only be prescribed and given by a healthcare professional who has experience in the use of this type of medicine given into a vein.
Lijek Zoledronatna kiselina Accord izdaje se samo na liječnički recept i smiju ga propisivati i primjenjivati samo zdravstveni djelatnici s iskustvom u intravenskoj primjeni ove vrste lijekova.
Zoledronic Acid Accord concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Koncentrat Zoledronatna kiselina Accord ne smije se miješati s kalcijem ili drugim otopinama za infuziju koje sadrže dvovalentne katione, kao što je otopina Ringerovog laktata, i treba se primijeniti kao jednokratna intravenska otopina kroz posebnu infuzijsku liniju.
Zoledronic Acid Accord contains sodium.
Zoledronatna kiselina Accord sadrži natrij
Zoledronic Acid Accord is a medicine that contains the active substance zoledronic acid.
Zoledronatna kiselina Accord je lijek koji sadrži zoledronatnu kiselinu kao djelatnu tvar.
Zoledronic Acid Accord is a ‘generic medicine’.
Zoledronatna kiselina Accord je „generički lijek”.
Zoledronic Acid Accord is given as a drip (infusion) into a vein which should take at least
Zoledronatna kiselina Accord daje se u venu kao infuzija (drip) u trajanju od najmanje
Zoledronic Acid Accord is supplied as a liquid concentrate in a vial.
Zoledronatna kiselina Accord isporučuje se kao tekući koncentrat u bočici.
Zoledronic Acid Accord must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronatnu kiselinu Accord smije davati samo zdravstveni djelatnici iskusni u davanju bisfosfonata intravenskim putem, tj. u venu.
Zoledronic Acid Accord must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates.
Zoledronatnu kiselinu Accord bolesnicima smiju propisivati i primjenjivati samo zdravstveni djelatnici s iskustvom u intravenskoj primjeni bisfosfonata.
Zoledronic acid Actavis 4 mg/5 ml concentrate for solution for infusion is supplied as packs containing 1, 4 or 10 vials.
Zoledronatna kiselina Actavis 4 mg/5 ml koncentrat za otopinu za infuziju isporučuje se u pakiranjima koja sadrže 1, 4 ili 10 bočica.
Zoledronic acid Actavis 4 mg/5 ml concentrate for solution for infusion, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.
Zoledronatnu kiselinu Actavis 4 mg/5 ml koncentrat za otopinu za infuziju, dodatno razrijeđenu u 100 ml (vidjeti dio 6.6), potrebno je dati kao jednokratnu intravensku infuziju u trajanju od najmanje 15 minuta.
Zoledronic acid Actavis is a ‘generic medicine’.
Zoledronatna kiselina Actavis je „generički lijek”.
Zoledronic acid Actavis is given as a drip (infusion) into a vein which should take at least
Zoledronatna kiselina Actavis daje se u venu kao infuzija (drip) u trajanju od najmanje
Zoledronic acid Actavis is supplied as a clear and colourless concentrate for solution for infusion (sterile concentrate) in a plastic vial.
Zoledronatna kiselina Actavis isporučuje se kao bistri i bezbojni koncentrat za otopinu za infuziju (sterilni koncentrat) u plastičnoj bočici.
Zoledronic acid Actavis must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Zoledronatna kiselina Actavis ne smije se miješati s kalcijem ili drugim otopinama za infuziju koje sadrže dvovalentne katione, kao što je otopina Ringerovog laktata, i treba se primijeniti kao jednokratna intravenska otopina kroz posebnu infuzijsku liniju.
Zoledronic acid Actavis must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronatnu kiselinu Actavis smiju davati samo zdravstveni djelatnici iskusni u davanju bisfosfonata intravenskim putem, tj. u venu.
Zoledronic acid Actavis treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment.
Liječenje bolesnika s hiperkalcemijom izazvanom tumorom koji imaju i teško oštećenje funkcije bubrega Zoledronatnom kiselinom Actavis dolazi u obzir tek nakon procjene rizika i koristi od liječenja.
Zoledronic acid Actavis treatment should be resumed at the same dose as that given prior to treatment interruption.
Liječenje Zoledronatnom kiselinom Actavis smije se nastaviti istom dozom koja se davala prije prekida liječenja.
Zoledronic acid does not inhibit human P450 enzymes in vitro, shows no biotransformation and in animal studies < 3 % of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.
Zoledronatna kiselina ne inhibira ljudske P450 enzime in vitro, ne metabolizira se, a u ispitivanjima na životinjama < 3% primijenjene doze otkrilo se u izmetu, što pokazuje da funkcija jetre nema važnu ulogu u farmakokinetici zoledronatne kiseline.
Zoledronic acid does not inhibit human P450 enzymes in vitro, shows no biotransformation and in animal studies < 3% of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.
Zoledronatna kiselina ne inhibira ljudske P450 enzime in vitro, ne metabolizira se, a u ispitivanjima na životinjama < 3% primijenjene doze otkrilo se u fecesu, što pokazuje da funkcija jetre nema važnu ulogu u farmakokinetici zoledronatne kiseline.
Zoledronic acid does not inhibit human P450 enzymes in vitro, shows no biotransformation and in animal studies < 3% of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.
Zoledronatna kiselina ne inhibira ljudske P450 enzime in vitro, ne metabolizira se, a u ispitivanjima na životinjama < 3% primijenjene doze otkrilo se u izmetu, što pokazuje da funkcija jetre nema važnu ulogu u farmakokinetici zoledronatne kiseline.
Zoledronic acid does not inhibit human P450 enzymes in vitro, shows no biotransformation and in animal studies < 3% of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.
Zoledronatna kiselina ne inhibira ljudske P450 enzime in vitro, ne metabolizira se, a u ispitivanjima na životinjama < 3% primijenjene doze otkrilo se u stolici, što pokazuje da funkcija jetre nema značajnu ulogu u farmakokinetici zoledronatne kiseline.
Zoledronic acid does not inhibit human P450 enzymes in vitro, shows no biotransformation and in animal studies < 3% of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.
Zoledronatna kiselina ne inhibira ljudske P450 enzime in vitro, ne metabolizira se, a u ispitivanjima na životinjama <3% primijenjene doze otkrilo se u izmetu, što pokazuje da funkcija jetre nema važnu ulogu u farmakokinetici zoledronatne kiseline.
Zoledronic acid has been associated with reports of renal dysfunction.
Prijavljena je povezanost zoledronatne kiseline i disfunkcije bubrega.
Zoledronic acid has been associated with reports of renal dysfunction.
Zabilježena je povezanost zoledronatne kiseline s poremećajem funkcije bubrega.
Zoledronic Acid Hospira (5 mg in 100 ml ready-to-infuse solution) is administered via an infusion line and given at a constant infusion rate.
Zoledronatnu kiselinu Hospira (5 mg/100 ml otopina spremna za infuziju) treba primijeniti putem infuzijske linije jednakom brzinom infuzije.
Zoledronic Acid Hospira 4 mg/100 ml (to appear in roundel) solution for infusion Zoledronic acid
Zoledronatna kiselina Hospira 4 mg/100 ml (pojavljuje se u krugu) otopina za infuziju zoledronatna kiselina
Zoledronic Acid Hospira 4 mg/100 ml solution for infusion can be used immediately without further preparation for patients with normal renal function.
Zolendrotana kiseline Hospira 4mg/100ml otopina za infuziju može se upotrijebiti odmah bez dodatne pripreme za bolesnike s normalnom funkcijom bubrega.
Zoledronic Acid Hospira 4 mg/100 ml solution for infusion contains 4 mg zoledronic acid in 100 ml of infusion solution for immediate use in patients with normal renal function.
Zoledronatna kiselina Hospira 4 mg/100 ml otopina za infuziju sadrži 4 mg zoledronatne kiseline u 100 ml otopine za infuziju za neposrednu primjenu u bolesnika s normalnom funkcijom bubrega.
Zoledronic Acid Hospira 4 mg/5 ml Sterile concentrate IV
Zoledronatna kiselina Hospira 4 mg/5 ml sterilni koncentrat i.v.
Zoledronic Acid Hospira 5 mg/100 ml (to appear in roundel) solution for infusion Zoledronic acid
Zoledronatna kiselina Hospira 5 mg/100 ml (pojavljuje se u krugu) otopina za infuziju zoledronatna kiselina
Zoledronic Acid Hospira 5 mg/100 ml solution is used to treat Paget’s disease of the bone in adults.
Otopina Zoledronatne kiseline Hospira od 5 mg/100 ml koristi se za liječenje Pagetove bolesti kostiju u odraslih bolesnika.
Zoledronic Acid Hospira contains the active substance zoledronic acid.
Zoledronska kiselina sadrži djelatnu tvar zoledronatnu kiselinu.
Zoledronic Acid Hospira for infusion can be given to people aged 65 years and over.
Zoledronatna kiselina Hospira može se davati osobama u dobi od 65 ili više godina.
Zoledronic Acid Hospira has no or negligible influence on the ability to drive and use machines.
Zolendronatna kiselina Hospira nema ili ima zanemariv utjecaj na sposobnost upravljanja vozilima i rada na strojevima.
Zoledronic Acid Hospira has no or negligible influence on the ability to drive and use machines.
Zolendronatna kiselina Hospira nema ili ima zanemariv utjecaj na sposonost upravljanja vozilima ili rada na strojevima.
Zoledronic Acid Hospira is a clear and colourless solution.
Zoledronatna kiselina Hospira je bistra i bezbojna otopina.
Zoledronic Acid Hospira is a ‘generic’ and a ‘hybrid’ medicine.
Zoledronatna kiselina Hospira je „generički” i „hibridni lijek”.
Zoledronic Acid Hospira is contraindicated during breast-feeding (see section 4.3).
Zolendronatna kiselina Hospira je kontraindicirana tijekom dojenja (vidjeti dio 4.3).
Zoledronic Acid Hospira is contraindicated during pregnancy (see section 4.3).
Zolendronatna kiselina Hospira je kontraindicirana za vrijeme trudoće (vidjeti dio 4.3).
Zoledronic Acid Hospira is given as a drip (infusion) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line.
Zoledronatna kiselina Hospira daje se u venu kao infuzija u trajanju od najmanje 15 minuta i mora se primijeniti kao jednokratna intravenska otopina kroz zasebnu infuzijsku liniju.
Zoledronic Acid Hospira is given as a drip (infusion) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line.
Zoledronatna kiselina Hospira se daje u venu kao infuzija u trajanju od najmanje 15 minuta i mora se primijeniti kao jednokratna intravenska otopina kroz zasebnu infuzijsku liniju.
Zoledronic Acid Hospira is ready for use.
Zoledronatna kiselina Hospira je spremna za primjenu.
Zoledronic Acid Hospira is supplied as a liquid concentrate (referred to as a ‘concentrate for solution for infusion’ or ‘sterile concentrate’) in a vial.
Zoledronatna kiselina Hospira je tekući koncentrat (koji se naziva "koncentrat za otopinu za infuziju" ili "sterilni koncentrat") u bočici.
Zoledronic Acid Hospira is supplied as packs containing one bag.
Zoledronatna kiselina Hospira dolazi u pakovanjima koja sadrže jednu vrećicu.
Zoledronic Acid Hospira may also cause other side effects
Zolendronatna kiselina Hospira također može uzrokovati i druge nuspojave
Zoledronic Acid Hospira may work for longer than one year, and your doctor will let you know if you need to be treated again.
Zoledronatna kiselina Hospira može djelovati duže od godine dana, a liječnik će Vam reći ako se trebate ponovo liječiti.
Zoledronic Acid Hospira must not be mixed or given intravenously with any other medicinal product and must be given through a separate infusion line at a constant infusion rate.
Zoledronatna kiselina Hospira ne smije se miješati ili dati intravenski s drugim lijekovima te se mora primjeniti putem zasebne infuzijske linije s uz konstantnu brzinu infuzije.
Zoledronic Acid Hospira must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein (also referred to as ‘IV’ administration).
Zoledronatnu kiselinu Hospira smiju davati samo zdravstveni djelatnici iskusni u primjeni bisfosfonata intravenskim putem, tj. u venu (također poznato i kao i.v. primjena).
Zoledronic Acid Hospira must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronatnu kiselinu Hospira smije davati samo zdravstveni djelatnici iskusni u primjeni bisfosfonata intravenskim putem, tj. u venu (također poznato i kao i.v. primjena)..
Zoledronic Acid Hospira should be given as a single intravenous infusion in no less than 15 minutes.
Zoledronatnu kiselinu Hospira treba primjeniti kao jednokratnu intravensku infuziju u trajanju od najmanje 15 minuta.
Zoledronic Acid Hospira treatment should be resumed at the same dose as that given prior to treatment interruption.
Liječenje zoledronatnom kiselinom treba nastaviti istom dozom koja se primjenjivala prije prekida liječenja.
Zoledronic Acid Hospira with food and drink
Zolendronatna kiselina Hospira sa hranom i tekućinama